Student Major/Year in School
biology, third year
Faculty Mentor Information
Stefan H. Bossmann, Department of Chemistry, College of Arts & Sciences
Abstract
Cancer continues to be among the leading causes of death worldwide. In 2018, there were approximately 9.6 million cancer deaths, just in the United States alone, there were 1.7 million new cancer cases and 600,000 deaths. That is why, there is an urgent need for better ways to battle cancer. Therefore, the goal of this project is to create a nanobiosensor which would have T1 and T2 based imaging capabilities to measure cancer enzymatic activity. The diagnostic tool would be useful to differentiate between benign and malignant tumors in-vivo and to quantify the effect of cancer treatments, such as chemo- and radiation- therapy. The biosensor is composed of a small (2-3 nm) Fe2O3 nanoparticle, which is a good T1 contrast agent, and a large (~50 nm) magnetic Fe/Fe3O4 nanoparticle, which is a good T2 contrast agent, linked via a consensus caspase sequence. The synthesis and characterization of the biosensor will be discussed.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Recommended Citation
soto, laura (2019). "Design of sensors for in-vivo detection of cancer related enzymes," Kansas State University Undergraduate Research Conference. https://newprairiepress.org/ksuugradresearch/2019/posters/43
Design of sensors for in-vivo detection of cancer related enzymes
Cancer continues to be among the leading causes of death worldwide. In 2018, there were approximately 9.6 million cancer deaths, just in the United States alone, there were 1.7 million new cancer cases and 600,000 deaths. That is why, there is an urgent need for better ways to battle cancer. Therefore, the goal of this project is to create a nanobiosensor which would have T1 and T2 based imaging capabilities to measure cancer enzymatic activity. The diagnostic tool would be useful to differentiate between benign and malignant tumors in-vivo and to quantify the effect of cancer treatments, such as chemo- and radiation- therapy. The biosensor is composed of a small (2-3 nm) Fe2O3 nanoparticle, which is a good T1 contrast agent, and a large (~50 nm) magnetic Fe/Fe3O4 nanoparticle, which is a good T2 contrast agent, linked via a consensus caspase sequence. The synthesis and characterization of the biosensor will be discussed.
